1. Executive Summary
2. Research Methodology
3. Breast Cancer
3.1 Overview
3.1.1 Causes
3.1.2 Symptoms
3.1.3 Stages
3.2 Types
3.2.1 Hormone receptor (HR)-positive
3.2.2 Human epidermal growth factor receptor 2 (HER2)-positive
3.2.3 Triple negative breast cancer (TNBC)
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Stage
4.2.2 Market Share by Type
4.2.3 Market Share by Region
5. Market Segmentation - Drug Type
5.1 HER2 Inhibitors
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 CDK4/6 Inhibitors
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.3 Aromatase Inhibitors
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Drug Types
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 Germany
6.2.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 Market by Nations
6.3.3 Japan
6.3.3.1 Market Sizing (Actual & Forecasted)
6.3.3.2 Market Share by Drugs
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Mergers & Acquisitions
7.1.2 Emergence of Novel Therapies
7.1.3 Advent of Personalized & Targeted Therapies
7.2 Growth Drivers
7.2.1 Prevalence of Breast Cancer
7.2.2 Ageing Population
7.2.3 Rapid Changes in Lifestyle
7.2.4 Increasing Public Awareness
7.3 Challenges
7.3.1 Patent Expirations of Blockbuster Drugs
7.3.2 Stringent Regulations
7.3.3 Lack of Awareness in LICs
7.3.4 High Prices of Therapies
8. Competitive Landscape
9. Company Profiles
9.1 F. Hoffman-La Roche AG
9.2 Novartis AG
9.3 Eli Lilly and Company
9.4 Pfizer Inc.
9.5 AstraZeneca PLC